FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520743273> ?p ?o ?g. }

• W1520743273 endingPage "181" @default.
• W1520743273 startingPage "176" @default.
• W1520743273 abstract "Objective To determine the characteristics of patients with germ cell cancer and bone metastases. Patients and Methods The case records of patients with known germ cell tumours ( GCTs ) within the A nglian G erm C ell C ancer G roup database between J anuary 2005 and M arch 2011 were reviewed retrospectively. Data were collected for histopathology, presence of bone metastases at diagnosis or relapse, site of bone metastases and imaging method used to confirm bone metastases, treatment received, response to treatment and overall survival. We present here the largest unselected cohort of bone metastases in patients with GCTs . Results In all, 2550 cases of GCTs were reviewed and there was bone involvement in 19 cases. The primary site was either testicular (13/19), mediastinal (1/19) or unknown (5/19). Most cases were non‐seminomatous GCTs (11/19, 58%) and only three cases of seminomatous GCTs (3/19, 16%) with five cases in which diagnosis was based on clinical history and significantly raised GCT markers (5/19, 26%). In all of these five cases β‐human chorionic gonadotrophin was raised and in three α‐fetoprotein was raised, consistent with non‐seminomatous GCT . There were bone metastases at diagnosis (0.51%, 13/2550) or at relapse (0.24%, 6/2550). The sites of bone metastases were the vertebrae (15/19, 79%), pelvis (3/19, 16%), ribs (3/19, 16%) and femur (2/19, 11%). Ten patients (53%) had solitary, and nine patients (47%) had multiple, sites of bone metastases. In patients presenting with bone metastases at diagnosis compared with relapse, the mortality rate was 23% (3/13) and 50% (3/6), respectively. After receiving one line of chemotherapy, nine patients (47%) remained in remission not requiring further treatment, six (32%) required further chemotherapy due to subsequent relapse, three (16%) died after first‐line chemotherapy and one was lost to follow‐up. At the time of data collection and based on the last clinic follow‐up, six patients (32%) had died with a median (interquartile range, IQR ) follow‐up of 11.5 (4.3, 24.8) months and 10 (53%) remained alive with a median ( IQR ) follow‐up of 26 (13.5, 48) months Three patients were lost to follow‐up. Of the known patients alive, eight (42%) remained in remission and two (11%) had recurrent disease requiring further treatment. Conclusion Although bone disease in germ cell cancer is rare, awareness of this condition is important and there is a need for prospective evaluation of patient characteristics, treatment approaches and survival outcome in this group of patients." @default.
• W1520743273 created "2016-06-24" @default.
• W1520743273 creator A5012800133 @default.
• W1520743273 creator A5013101383 @default.
• W1520743273 creator A5027476694 @default.
• W1520743273 creator A5042414917 @default.
• W1520743273 creator A5049902199 @default.
• W1520743273 creator A5052620856 @default.
• W1520743273 creator A5063466081 @default.
• W1520743273 creator A5070907717 @default.
• W1520743273 creator A5075038379 @default.
• W1520743273 creator A5088951258 @default.
• W1520743273 date "2013-06-25" @default.
• W1520743273 modified "2023-09-27" @default.
• W1520743273 title "Bone metastases in germ cell tumours: lessons learnt from a large retrospective study" @default.
• W1520743273 cites W1526035454 @default.
• W1520743273 cites W1956474138 @default.
• W1520743273 cites W1966365492 @default.
• W1520743273 cites W1985121112 @default.
• W1520743273 cites W2009472701 @default.
• W1520743273 cites W2011453854 @default.
• W1520743273 cites W2012395462 @default.
• W1520743273 cites W2015129821 @default.
• W1520743273 cites W2016177710 @default.
• W1520743273 cites W2016447107 @default.
• W1520743273 cites W2019842572 @default.
• W1520743273 cites W2034290314 @default.
• W1520743273 cites W2048902664 @default.
• W1520743273 cites W2059704175 @default.
• W1520743273 cites W2064841453 @default.
• W1520743273 cites W2080241168 @default.
• W1520743273 cites W2086752812 @default.
• W1520743273 cites W2114044600 @default.
• W1520743273 cites W2136788748 @default.
• W1520743273 cites W2139534064 @default.
• W1520743273 cites W2140226073 @default.
• W1520743273 cites W2141256658 @default.
• W1520743273 cites W2152286247 @default.
• W1520743273 cites W2157263358 @default.
• W1520743273 cites W2168588194 @default.
• W1520743273 cites W2418746042 @default.
• W1520743273 cites W2602689510 @default.
• W1520743273 cites W4243260619 @default.
• W1520743273 cites W44254208 @default.
• W1520743273 doi "https://doi.org/10.1111/bju.12218" @default.
• W1520743273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23795785" @default.
• W1520743273 hasPublicationYear "2013" @default.
• W1520743273 type Work @default.
• W1520743273 sameAs 1520743273 @default.
• W1520743273 citedByCount "31" @default.
• W1520743273 countsByYear W15207432732014 @default.
• W1520743273 countsByYear W15207432732015 @default.
• W1520743273 countsByYear W15207432732016 @default.
• W1520743273 countsByYear W15207432732017 @default.
• W1520743273 countsByYear W15207432732018 @default.
• W1520743273 countsByYear W15207432732019 @default.
• W1520743273 countsByYear W15207432732020 @default.
• W1520743273 countsByYear W15207432732022 @default.
• W1520743273 countsByYear W15207432732023 @default.
• W1520743273 crossrefType "journal-article" @default.
• W1520743273 hasAuthorship W1520743273A5012800133 @default.
• W1520743273 hasAuthorship W1520743273A5013101383 @default.
• W1520743273 hasAuthorship W1520743273A5027476694 @default.
• W1520743273 hasAuthorship W1520743273A5042414917 @default.
• W1520743273 hasAuthorship W1520743273A5049902199 @default.
• W1520743273 hasAuthorship W1520743273A5052620856 @default.
• W1520743273 hasAuthorship W1520743273A5063466081 @default.
• W1520743273 hasAuthorship W1520743273A5070907717 @default.
• W1520743273 hasAuthorship W1520743273A5075038379 @default.
• W1520743273 hasAuthorship W1520743273A5088951258 @default.
• W1520743273 hasConcept C121608353 @default.
• W1520743273 hasConcept C126322002 @default.
• W1520743273 hasConcept C126838900 @default.
• W1520743273 hasConcept C141071460 @default.
• W1520743273 hasConcept C142724271 @default.
• W1520743273 hasConcept C167135981 @default.
• W1520743273 hasConcept C2776212926 @default.
• W1520743273 hasConcept C2776694085 @default.
• W1520743273 hasConcept C2776938808 @default.
• W1520743273 hasConcept C2777783956 @default.
• W1520743273 hasConcept C2778357063 @default.
• W1520743273 hasConcept C2779013556 @default.
• W1520743273 hasConcept C544855455 @default.
• W1520743273 hasConcept C71924100 @default.
• W1520743273 hasConceptScore W1520743273C121608353 @default.
• W1520743273 hasConceptScore W1520743273C126322002 @default.
• W1520743273 hasConceptScore W1520743273C126838900 @default.
• W1520743273 hasConceptScore W1520743273C141071460 @default.
• W1520743273 hasConceptScore W1520743273C142724271 @default.
• W1520743273 hasConceptScore W1520743273C167135981 @default.
• W1520743273 hasConceptScore W1520743273C2776212926 @default.
• W1520743273 hasConceptScore W1520743273C2776694085 @default.
• W1520743273 hasConceptScore W1520743273C2776938808 @default.
• W1520743273 hasConceptScore W1520743273C2777783956 @default.
• W1520743273 hasConceptScore W1520743273C2778357063 @default.
• W1520743273 hasConceptScore W1520743273C2779013556 @default.
• W1520743273 hasConceptScore W1520743273C544855455 @default.
• W1520743273 hasConceptScore W1520743273C71924100 @default.

• next